| P2093 | author name string | Paul Martin | |
| | Andres F Carrion | |
| P2860 | cites work | Boceprevir for previously treated chronic HCV genotype 1 infection | Q24620576 |
| | An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases | Q24632766 |
| | Diagnosis, management, and treatment of hepatitis C: an update | Q29619682 |
| | Telaprevir for previously untreated chronic hepatitis C virus infection | Q29619800 |
| | The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 | Q29619974 |
| | Boceprevir for untreated chronic HCV genotype 1 infection | Q29620617 |
| | Frequencies of hepatitis B and C infections among haemodialysis and peritoneal dialysis patients in Asia-Pacific countries: analysis of registry data | Q33394541 |
| | Serologic and virologic profiles of hepatitis C infection in renal transplant candidates. New England Organ Bank Hepatitis C Study Group | Q33464534 |
| | Hepatitis C infection and the patient with end-stage renal disease | Q34708264 |
| | Hepatitis C virus infection and renal disease after renal transplantation | Q35757112 |
| | Renal transplant recipient with chronic hepatitis C who obtained sustained viral response after interferon-beta therapy | Q35969611 |
| | Hepatitis C virus antibody status and survival after renal transplantation: meta-analysis of observational studies | Q36124145 |
| | The impact of hepatitis C virus infection on survival in dialysis patients: meta-analysis of observational studies | Q36944054 |
| | Interferon monotherapy of chronic hepatitis C in dialysis patients: meta-analysis of clinical trials | Q37053900 |
| | Antiviral therapy of hepatitis C in chronic kidney diseases: meta-analysis of controlled clinical trials | Q37150375 |
| | Ribavirin in the treatment of chronic hepatitis C. | Q37195248 |
| | Hepatitis C virus and kidney disease | Q37229019 |
| | Hepatitis C infection and chronic renal diseases | Q37364331 |
| | Comorbidities and their impact on mortality in HCV and HCV-HIV-coinfected persons on dialysis | Q40027313 |
| | Treatment of dialysis patients with chronic hepatitis C using pegylated interferon and low-dose ribavirin. | Q42977964 |
| | Hepatitis C Infection Among Dialysis Patients: A Comparison Between Patients on Maintenance Haemodialysis and Continuous Ambulatory Peritoneal Dialysis | Q42986023 |
| | Alpha-interferon with ribavirin in the treatment of hemodialysis patients with hepatitis C. | Q42987340 |
| | Modelling how ribavirin improves interferon response rates in hepatitis C virus infection | Q42989468 |
| | Incidence of HCV infection in French hemodialysis units: a prospective study | Q42993875 |
| | Safety of interferon and ribavirin therapy in haemodialysis patients with chronic hepatitis C: results of a pilot study | Q43029970 |
| | The treatment of chronic hepatitis C with peginterferon alfa-2a (40 kDa) plus ribavirin in haemodialysed patients awaiting renal transplant | Q43036736 |
| | Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection--a pilot study | Q43674747 |
| | De novo glomerulonephritis in renal allografts with hepatitis C virus infection | Q44033369 |
| | National surveillance of dialysis-associated diseases in the United States, 2002. | Q45233196 |
| | Long-term impact of hepatitis B, C virus infection on renal transplantation | Q45736050 |
| | Clinical characteristics and mortality in hepatitis C-positive haemodialysis patients: a population based study | Q46499600 |
| | Anti-viral therapy in haemodialysed HCV patients: efficacy, tolerance and treatment strategy. | Q50556069 |
| | Comparing survival between peritoneal dialysis and hemodialysis treatment in ESRD patients with chronic hepatitis C infection. | Q51790275 |
| | KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. | Q55049598 |
| | Pegylated interferon -2a versus standard interferon -2a for treatment-naive dialysis patients with chronic hepatitis C: a randomised study | Q57205337 |
| | Hepatitis C associated glomerulonephritis | Q71596882 |
| | Treatment of chronic hepatitis C with recombinant alpha 2b interferon in kidney transplant recipients: preliminary results and side effects | Q72603253 |
| | Impact of HCV infection on development of posttransplantation diabetes mellitus in renal allograft recipients | Q73794849 |
| | Effect of interferon-alfa treatment in renal transplant recipients with chronic hepatitis C | Q77632399 |
| | Hepatitis C infection, time in renal-replacement therapy, and outcome after kidney transplantation | Q80572083 |
| | Interferon therapy in hemodialysis patients with chronic hepatitis C: study of tolerance, efficacy and post-transplantation course | Q81691472 |
| P433 | issue | 3 | |
| P921 | main subject | chronic renal insufficiency | Q736715 |
| P304 | page(s) | 91-94 | |
| P577 | publication date | 2012-07-23 | |
| P1433 | published in | Clinical liver disease | Q27726171 |
| P1476 | title | Hepatitis C viral infection in patients with chronic kidney disease | |
| P478 | volume | 1 | |